Intensive Statin Therapy and Diabetes
High-dose statin therapy has been linked with a higher incidence of diabetes when compared with moderate-dosage statins, which are used to lower cholesterol levels. However, the cardiovascular benefits of intensive-dose statins are considered a greater a benefit than the increased risk of diabetes.
A meta-analysis of randomized trials was conducted to compare high-dose with moderate-dose statins in 1,000 patients. Patients were observed for more than a year. Five of the studies meeting criteria compared moderate doses of atorvastatin (Lipitor[R]), simvastatin (Zocor[R]), or pravastatin (Pravachol[R]) with high doses of atorvastatin or simvastatin alone. The total number of enrolled patients who did not have diabetes at the outset was 32,752. Patients were followed for a mean of almost five years. Diabetes was identified through reports of adverse events, by prescriptions of glucose-lowering medications, or by elevated fasting plasma glucose measurements. During the follow-up, diabetes occurred more often in patients receiving intensive-dose developed diabetes than in those receiving standard-dose statin therapy.
For every 1,000 patients per year, two additional cases …
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information: Article title: Intensive Statin Therapy and Diabetes. Contributors: Not available. Magazine title: Nutrition Health Review. Issue: 106 Publication date: Summer 2011. Page number: 18. © 1996 Vegetus Publications. COPYRIGHT 2011 Gale Group.